Hodgkin's disease+1
Not recruitingStudy of Pembrolizumab with Hyaluronidase for Patients with Relapsed or Refractory Hodgkin Lymphoma or Primary Mediastinal Large B-cell Lymphoma
Study of Pembrolizumab with Hyaluronidase for Patients with Relapsed or Refractory Hodgkin Lymphoma or Primary Mediastinal Large B-cell Lymphoma
- Disease:Hodgkin's diseasePrimary mediastinal large B-cell lymphoma
- Substances:Pembrolizumab
Spain- Participants:18–64 years · 65+ years
- Substances:Pembrolizumab
- Sponsor:Merck Sharp & Dohme LLC









